199 related articles for article (PubMed ID: 36073513)
1. Targeting dual oncogenic machineries driven by TAL1 and PI3K-AKT pathways in T-cell acute lymphoblastic leukemia.
Lim FQ; Chan AS; Yokomori R; Huang XZ; Theardy MS; Yeoh AEJ; Tan SH; Sanda T
Haematologica; 2023 Feb; 108(2):367-381. PubMed ID: 36073513
[TBL] [Abstract][Full Text] [Related]
2. TAL1 cooperates with PI3K/AKT pathway activation in T-cell acute lymphoblastic leukemia.
Thielemans N; Demeyer S; Mentens N; Gielen O; Provost S; Cools J
Haematologica; 2022 Oct; 107(10):2304-2317. PubMed ID: 35354248
[TBL] [Abstract][Full Text] [Related]
3. TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
Tan SH; Tan TK; Yokomori R; Liao M; Huang XZ; Yeoh AEJ; Sanda T
Leukemia; 2023 Oct; 37(10):1969-1981. PubMed ID: 37591943
[TBL] [Abstract][Full Text] [Related]
4. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
Smith C; Goyal A; Weichenhan D; Allemand E; Mayakonda A; Toprak U; Riedel A; Balducci E; Manojkumar M; Pejkovska A; Mücke O; Sollier E; Bakr A; Breuer K; Lutsik P; Hermine O; Spicuglia S; Asnafi V; Plass C; Touzart A
Haematologica; 2023 May; 108(5):1259-1271. PubMed ID: 36632736
[TBL] [Abstract][Full Text] [Related]
5. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
[TBL] [Abstract][Full Text] [Related]
6. Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia.
Patel B; Kang Y; Cui K; Litt M; Riberio MS; Deng C; Salz T; Casada S; Fu X; Qiu Y; Zhao K; Huang S
Leukemia; 2014 Feb; 28(2):349-61. PubMed ID: 23698277
[TBL] [Abstract][Full Text] [Related]
7. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
[TBL] [Abstract][Full Text] [Related]
8. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia.
Mansour MR; Sanda T; Lawton LN; Li X; Kreslavsky T; Novina CD; Brand M; Gutierrez A; Kelliher MA; Jamieson CH; von Boehmer H; Young RA; Look AT
J Exp Med; 2013 Jul; 210(8):1545-57. PubMed ID: 23857984
[TBL] [Abstract][Full Text] [Related]
9. Aberrant activation of the GIMAP enhancer by oncogenic transcription factors in T-cell acute lymphoblastic leukemia.
Liau WS; Tan SH; Ngoc PCT; Wang CQ; Tergaonkar V; Feng H; Gong Z; Osato M; Look AT; Sanda T
Leukemia; 2017 Aug; 31(8):1798-1807. PubMed ID: 28028313
[TBL] [Abstract][Full Text] [Related]
10. S1P-S1PR3-RAS promotes the progression of S1PR3
Zhu D; Jiang T; Ma D; Zhang H; Zhang J; Lv W; Gong M; Wang H; Liu Z; Su H; Zeng L; Liu S; Tang S; Yang B; Tshavuka FI; Fu G; Liu Z; Peng D; Liu H; Yan Z; Cao Z; Zhao H; He TC; Yu J; Shu Y; Zou L
Leukemia; 2023 Oct; 37(10):1982-1993. PubMed ID: 37591940
[TBL] [Abstract][Full Text] [Related]
11. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.
Sanda T; Lawton LN; Barrasa MI; Fan ZP; Kohlhammer H; Gutierrez A; Ma W; Tatarek J; Ahn Y; Kelliher MA; Jamieson CH; Staudt LM; Young RA; Look AT
Cancer Cell; 2012 Aug; 22(2):209-21. PubMed ID: 22897851
[TBL] [Abstract][Full Text] [Related]
12. Regulatory mechanisms and context-dependent roles of TAL1 in T-cell acute lymphoblastic leukemia.
Ong JZL; Tan TK; Wang L; Tan SH; Sanda T
Haematologica; 2024 May; 109(5):1359-1372. PubMed ID: 37855064
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia.
Tan TK; Zhang C; Sanda T
Int J Hematol; 2019 Jan; 109(1):5-17. PubMed ID: 30145780
[TBL] [Abstract][Full Text] [Related]
14. Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
[TBL] [Abstract][Full Text] [Related]
15. TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
Wu Y; Hu Y; Yu X; Zhang Y; Huang X; Chen S; Li Y; Zeng C
Biochem Biophys Res Commun; 2019 Nov; 519(2):234-239. PubMed ID: 31493871
[TBL] [Abstract][Full Text] [Related]
16. Isoforms of the TAL1 transcription factor have different roles in hematopoiesis and cell growth.
Sharma A; Mistriel-Zerbib S; Najar RA; Engal E; Bentata M; Taqatqa N; Dahan S; Cohen K; Jaffe-Herman S; Geminder O; Baker M; Nevo Y; Plaschkes I; Kay G; Drier Y; Berger M; Salton M
PLoS Biol; 2023 Jun; 21(6):e3002175. PubMed ID: 37379322
[TBL] [Abstract][Full Text] [Related]
17. MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
Astolfi A; Vendemini F; Urbini M; Melchionda F; Masetti R; Franzoni M; Libri V; Serravalle S; Togni M; Paone G; Montemurro L; Bressanin D; Chiarini F; Martelli AM; Tonelli R; Pession A
Oncotarget; 2014 Jan; 5(1):120-30. PubMed ID: 24334727
[TBL] [Abstract][Full Text] [Related]
18. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.
Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta induces degradation of TAL1/SCL by the ubiquitin-proteasome pathway through AKT-mediated phosphorylation.
Terme JM; Lhermitte L; Asnafi V; Jalinot P
Blood; 2009 Jun; 113(26):6695-8. PubMed ID: 19406989
[TBL] [Abstract][Full Text] [Related]
20. The enhancer RNA
Tan SH; Leong WZ; Ngoc PCT; Tan TK; Bertulfo FC; Lim MC; An O; Li Z; Yeoh AEJ; Fullwood MJ; Tenen DG; Sanda T
Blood; 2019 Jul; 134(3):239-251. PubMed ID: 31076442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
